CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $16.60.

A number of equities research analysts have weighed in on the stock. William Blair cut shares of CVRx from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 1st. Craig Hallum started coverage on shares of CVRx in a report on Wednesday, May 1st. They issued a “buy” rating and a $23.00 target price for the company. JPMorgan Chase & Co. cut CVRx from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $36.00 to $13.00 in a research note on Wednesday, May 1st. Piper Sandler lowered their price target on CVRx from $33.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group cut their price objective on CVRx from $32.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st.

Institutional Trading of CVRx

A number of large investors have recently modified their holdings of the stock. Johnson & Johnson grew its stake in CVRx by 17.4% during the 1st quarter. Johnson & Johnson now owns 4,103,430 shares of the company’s stock worth $74,723,000 after purchasing an additional 607,855 shares in the last quarter. Vanguard Group Inc. grew its position in shares of CVRx by 5.6% during the first quarter. Vanguard Group Inc. now owns 594,312 shares of the company’s stock worth $10,822,000 after buying an additional 31,720 shares in the last quarter. Silvercrest Asset Management Group LLC increased its stake in shares of CVRx by 70.7% during the first quarter. Silvercrest Asset Management Group LLC now owns 253,968 shares of the company’s stock worth $4,625,000 after buying an additional 105,198 shares during the period. Parkman Healthcare Partners LLC raised its holdings in CVRx by 8.0% in the fourth quarter. Parkman Healthcare Partners LLC now owns 240,000 shares of the company’s stock valued at $7,546,000 after acquiring an additional 17,880 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its stake in CVRx by 47.2% in the third quarter. Schonfeld Strategic Advisors LLC now owns 59,900 shares of the company’s stock worth $909,000 after acquiring an additional 19,200 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Stock Up 7.1 %

Shares of NASDAQ CVRX opened at $11.17 on Thursday. The company has a market capitalization of $241.27 million, a P/E ratio of -4.52 and a beta of 1.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 12.18 and a quick ratio of 10.87. The company has a 50 day simple moving average of $9.86 and a 200-day simple moving average of $18.59. CVRx has a 1 year low of $6.40 and a 1 year high of $33.13.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, April 30th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.51). The business had revenue of $10.77 million for the quarter, compared to analyst estimates of $11.60 million. CVRx had a negative return on equity of 66.05% and a negative net margin of 123.58%. On average, equities research analysts predict that CVRx will post -2.39 earnings per share for the current year.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.